secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001104659-25-055180
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia starts YUTREPIA shipments after FDA approval; court denies UTHR injunction
--------------------------------------------------------------------------------

- First commercial shipment of YUTREPIA (treprostinil) inhalation powder to specialty pharmacies scheduled.
- FDA approved YUTREPIA on May 23, 2025 for PAH and PH-ILD.
- Court denied United Therapeutics' motion for preliminary injunction and TRO on May 30, 2025.
- Court concluded UTHR unlikely to succeed on merits; Liquidia's motion to dismiss remains pending.
- CEO cites rapid launch: sales force active, product listed with compendia within one week.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925055180/0001104659-25-055180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925055180/tm2516834d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer